Heidi Braun
Internal Medicine · Pooler, GANPI 1508943309
Payments from drug & device makers
Across 124 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$582
- Axsome Therapeutics, Inc.$572
- Novo Nordisk$294
- Lilly USA, LLC$219
- GSK$192
- AbbVie$188
- plus $964 from 16 others
What the payments were for
- Food & beverage$3,010100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 23 | $582 |
| Axsome Therapeutics, Inc. | 16 | $572 |
| Novo Nordisk | 15 | $294 |
| Lilly USA, LLC | 14 | $219 |
| GSK | 6 | $192 |
| AbbVie(2 entities) | 5 | $188 |
| Vanda Pharmaceuticals Inc. | 8 | $160 |
| AstraZeneca | 8 | $140 |
| Dexcom, Inc. | 1 | $103 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $94 |
| Teva Pharmaceuticals USA, Inc. | 2 | $93 |
| Pfizer | 4 | $73 |
| Novartis | 4 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $60 |
| Lundbeck LLC | 2 | $39 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$287
- Repatha$245
- VIBERZI$132
- RYBELSUS$105
- DEXCOM G6 TRANSMITTER$103
How this compares
$3,010 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 39 | $44,952 |
| JardianceEmpagliflozin | 31 | $31,269 |
| JanuviaSitagliptin Phosphate | 25 | $21,474 |
| OzempicSemaglutide | 18 | $16,534 |
| InvokanaCanagliflozin | 15 | $7,122 |
| MyrbetriqMirabegron | 14 | $6,137 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $5,905 |
| DapagliflozinDapagliflozin Propanediol | 11 | $4,431 |
| EdarbiAzilsartan Medoxomil | 11 | $2,514 |
| Pregabalin | 30 | $1,201 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 52 | $1,035 |
| Cholestyramine LightCholestyramine | 11 | $536 |
| Losartan Potassium | 36 | $523 |
| Levothyroxine Sodium | 77 | $512 |
| Olmesartan Medoxomil | 35 | $459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $219 | $44,95239 claims |
| Novo NordiskOzempic | $294 | $16,53418 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $27 | $2,51411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Pooler
- Paul BradleySavannah$76.4M
- Kimball JohnsonAtlanta$51.1M
- Bram WieskopfWoodstock$21.9M
- Dwight BlakeUnion City$13.3M
- Charlotte Grayson-MathisFayetteville$9.6M
- Christopher RecknorGainesville$9.2M
- James HarperJohns Creek$9.2M
- Robert Springer IiiAtlanta$5.3M
- Thomas MoriaritySavannah$4.6M
- Charles KempAlbany$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.